The U.S. Food and Drug Administration flagged two procedural lapses related to laboratory controls at Lupin Ltd.’s oral solid dosage facility in Nagpur, Maharashtra.
Queries sent to Lupin via email have note received a response till now. The company is also yet to comment on the steps being taken to address these issues and the expected timelines for resolution.
Shares of Lupin closed 1.43% higher on Thursday, compared to a 0.71% rise in the benchmark Sensex.
WRITTEN BY
ADVERTISEMENT
RECOMMENDED FOR YOU
FY26 Looks Solid In Terms Of Revenue And Margin Improvement, Says Ashiana Housing Whole Time Director
Jul 15, 2025
Indogulf Cropsciences Shares List At IPO Price Of Rs 111 Despite Solid Public Issue
Jul 03, 2025
Explained: What Is 'Credit Hunger'? How It Affects Your Credit Score
Jun 22, 2025
Samsung Galaxy S24 Price Drops By Rs 47,000: How To Get The Best Deal On Flipkart
Jun 20, 2025
POPULAR
1
AI Express Boeing 737 Plane Faces Tech Issue; Airline Cancels Lucknow-Dubai Flight
2
India US Trade Deal News Updates: Trump Says Close To Ink Pact With India
3
ALPA India Raises Red Flag Over Misuse Of Pilot Rest Norms; DGCA May Step In
4
IndiGo's Delhi–Goa Flight Makes Emergency Landing In Mumbai After Engine Failure: Report
5